The annual US grant to GAVI is requested at US$ 145 million, an increase of US$ 15 million
Geneva, 13 February 2012 - The GAVI Alliance expresses its deep appreciation to the US government for the increase in funding proposed in President Obama’s fiscal year 2013 budget request to Congress on 13 February.
The annual US grant to GAVI is requested at US$ 145 million, an increase of US$ 15 million over the Administration’s proposed allocation of US$ 130 million to GAVI for FY 2012.
Achieving massive impact
“We are grateful to the President and USAID Adminstrator Raj Shah for their leadership at this challenging economic time. The funding requested will be used to procure and deliver vaccines against diseases including pneumonia and diarrhoea. GAVI and its partners, including USAID, are working together to fund the immunisation of an additional quarter of a billion children by 2015. This will have a massive impact” said Seth Berkley, CEO of the GAVI Alliance.
The GAVI Alliance is a public-private global health partnership committed to saving children’s lives and protecting people’s health by increasing access to immunisation in poor countries.
We appreciate the steadfast support of the United States as our Alliance works to reduce child deaths which can be prevented with powerful new vaccines.
Preventing child deaths
At a donor conference in June 2011, the United States was among numerous governments and the Bill & Melinda Gates Foundation that pledged new resources to ensure that GAVI could meet the demand for new vaccines over the period of 2012-2014. This year alone, more than 10 million additional children in over a dozen countries are expected to receive vaccines which protect against the two of the biggest killers of children, pneumonia and diarrhoea.
“We appreciate the steadfast support of the United States as our Alliance works to reduce child deaths which can be prevented with powerful new vaccines.”
The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society organisations, the Bill & Melinda Gates Foundation and other private philanthropists.